Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Active Surveillance vs Continued Systemic Immunotherapy in Very-High-Risk NMIBC
NCT07625527Phase 2Recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- May 2026
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-muscle-invasive bladder cancer (NMIBC) (4 cohorts), sponsored by The Second Hospital of Tianjin Medical University. Primary endpoint: Bladder-intact event-free survival up to 2 years. Started May 2026; status: recruiting.
02
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07625527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07625527.